In today’s Pharmaceutical Executive Daily, Caribou Biosciences discontinues its allogeneic CAR-T programs vispa-cel and Cb-011, Kamal Biswas argues that continuous, AI-enabled quality management maturity can flag a brewing hundred-million-dollar problem months before an FDA inspection would, and FDA approves Pfizer’s Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for HER2-positive metastatic breast cancer.
Caribou Biosciences has discontinued its two allogeneic CAR-T programs, vispa-cel, an anti-CD19 therapy for relapsed or refractory B-cell non-Hodgkin lymphoma that the company says is pivotal trial-ready, and Cb-011, an anti-BCMA candidate for relapsed or refractory multiple myeloma that showed deep, durable responses in the Phase I CaMMouflage trial. Chief executive officer Rachel Haurwitz says the financing environment for allogeneic CAR-T therapies has made the programs too difficult to fund and that the decision is in no way a reflection of their belief in patient benefit, as the company cuts most of its workforce by the fourth quarter of 2026 while reviewing strategic alternatives including a merger or sale.
Kamal Biswas argues that passing an FDA inspection says little about whether a major revenue risk is already forming, and that continuous, AI-enabled quality management maturity, or QMM, can surface that risk months before it reaches the P&L. Biswas points to a sample site alert showing a quality maturity score sliding from 4.1 to 3.6 over 90 days as the kind of early warning traditional inspection-based oversight would miss.
Finally, FDA has approved Pfizer’s Tukysa (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. The approval rests on the Phase III HER2CLIMB-05 trial, in which the combination extended median progression-free survival by 8.6 months, to 24.9 months versus 16.3 months with placebo plus the two antibodies, with a hazard ratio of 0.64.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
